ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of a Short Term Exercise Schedule on Oral Iron Bio-availability and Iron Incorporation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01730521
Recruitment Status : Completed
First Posted : November 21, 2012
Last Update Posted : September 13, 2013
Sponsor:
Information provided by (Responsible Party):
Prof. Michael B. Zimmermann, Swiss Federal Institute of Technology

Brief Summary:

Iron metabolism may undergo changes during exercise, with reductions in classical iron status markers due to a variety of postulated mechanism which include hemodilution, increased iron loss, hemolysis and increased iron storage in muscles. Furthermore, it has been reported that vigorous training increases hepcidin, a central regulatory peptide in iron metabolism. This increase has been ascribed to the presence of subclinical inflammation. Increased hepcidin levels may reduce iron bioavailability and iron incorporation in erythrocytes.

Twenty healthy men subjects will be recruited as subjects for this study. Subjects should be generally healthy, with no history of blood donation in the last 6 months, should weigh less than 85 Kg, and not take iron supplements and/or multivitamin supplements. Subjects should have familiarity to sports and running, but not currently (i.e. in the past 3 months) training for more than 1h per week on average.

The aim of this study is to measure an iron bioavailability during a resting and an exercise phase lasting approx. 14 days with training sessions on alternate days. Subjects will participate in both restign and exercising protocols and act as their own controls during the study. Iron bioavailability will be measured via the incorporation of stable isotopic labels 14 days after administration. To control for changes in blood volume during the course of the study, blood volume of the participating subjects will be measured before and after the exercise phase with the CO-rebreathing method.

Measurement of iron bioavailability and iron incorporation in a resting and exercising phase will allow determine if the increased level of hepcidin seen in in exercise will induce a lower iron bioavailability and iron incorporation during exercise.


Condition or disease Intervention/treatment
Generally Healthy Behavioral: Exercise (Running)

Study Type : Observational
Actual Enrollment : 10 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Effect of a Short Term Exercise Schedule on Oral Iron Bio-availability and Iron Incorporation
Study Start Date : October 2012
Actual Primary Completion Date : December 2012
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Difference in Iron bioavailabilty exercise and resting phase
the subjects will act as their own control during the study
Behavioral: Exercise (Running)
the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.




Primary Outcome Measures :
  1. Iron bioavailability from Stable isotopic labels [ Time Frame: Up to 2 months ]

Secondary Outcome Measures :
  1. Blood volume increase during exercise [ Time Frame: Up to 2 months ]

Other Outcome Measures:
  1. Hepcidin levels and inflammation markers (C-Reactive Protein, 1-Alpha acid glycoprotein) [ Time Frame: Up to 2 months ]

Biospecimen Retention:   Samples With DNA
Whole blood and serum samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects studying or working at the University of Zürich or ETH Zürich
Criteria

Inclusion Criteria:

  • men, Generally Healthy age between 18-50 years;
  • BMI between 18-25;
  • nonanemic (Hb < 120 g/L);
  • no intake of vitamins and nutritional supplements;
  • no recent blood donation (<4 months);
  • no previous participation in studies with stable iron isotopes in the past.

Exclusion Criteria:

  • Chronic diseases, Metabolic diseases, GI tract diseases (self reported)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01730521


Locations
Switzerland
ETH Zürich
Zürich, Switzerland, 8092
Sponsors and Collaborators
Swiss Federal Institute of Technology
Investigators
Principal Investigator: Diego Moretti, PhD University of Zurich

Additional Information:
Publications:
Responsible Party: Prof. Michael B. Zimmermann, Professor, MD, Swiss Federal Institute of Technology
ClinicalTrials.gov Identifier: NCT01730521     History of Changes
Other Study ID Numbers: EK 2012-N-27
First Posted: November 21, 2012    Key Record Dates
Last Update Posted: September 13, 2013
Last Verified: September 2013

Additional relevant MeSH terms:
Iron
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs